BioNTech

生物新技术公司转型关键期：肿瘤管线能否接棒新冠疫苗收入？

Brett Shapiro - January 19, 2026

BioNTech战略转型获市场青睐，分析师上调预期至2026年

Brett Shapiro - January 18, 2026

生物技术巨头BioNTech转型加速：肿瘤管线成2026年核心引擎

angelina - January 15, 2026

BioNTech战略转型：千亿现金储备驱动肿瘤学新蓝图

kashif hafeez - January 14, 2026

2026年：BioNTech转型之路的关键考验

January 13, 2026

BioNTech战略转型：肿瘤管线布局成为市场新焦点

angelina - January 12, 2026

BioNTech战略转型：肿瘤疗法成为核心增长引擎

angelina - January 10, 2026

BioNTech股价遭遇技术性阻力

Brett Shapiro - January 9, 2026

德国mRNA双雄合体：BioNTech正式完成对CureVac的收购

angelina - January 7, 2026

BioNTech开启并购新纪元：整合CureVac mRNA技术，全力押注肿瘤疗法

Brett Shapiro - January 6, 2026

BioNTech股价：十字路口的机遇与挑战

kashif hafeez - January 1, 2026

BioNTech战略转型：后疫情时代的肿瘤学征途

Brett Shapiro - December 30, 2025

生物技术巨头战略转型：BioNTech全力押注肿瘤疗法新赛道

December 28, 2025

BioNTech战略转型：并购CureVac重塑mRNA产业格局

angelina - December 28, 2025

BioNTech Consolidates mRNA Sector with CureVac Acquisition Finalized

December 24, 2025

123 4 Page 2 of 4